ERBB2 and neoplasm: The ES2B-C001 vaccine administered with adjuvant completely inhibited tumor growth in FVB mice challenged with a human HER-2-positive cell line (named QD), and mice remained tumor-free for more than one year after cell injection, whereas all control mice developed progressive tumor within 1–2 months.